The current guidelines surrounding Ki-67 and its role in therapeutic decision making are controversial: The most recent update from the International Ki-67 Working Group accepted Ki-67 as a prognostic marker in breast carcinoma, however, concluded that clinical utility is evident only for prognostic estimation in Luminal disease to guide therapeutic decision-making regarding adjuvant chemotherapy prescription. This evidence concerns the gene MKI67 and breast carcinoma.